Skip to main content

Perphenazine

Brand names: Perphenazine

Phenothiazine Oral

At a glance

Medicare prescriptions, 2024
138,289
Medicare drug cost
$7.6M
Average cost per prescription
$55.06
Clinicians who prescribed it
5,713

Where it is prescribed

Loading map…

List the prescribers in any state, county, city or ZIP code →

What it is used for

Perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. Perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation.

From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)

Boxed warning

WARNING Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with…

The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.

Who prescribes it

All prescribers, by place, name or specialty →

Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.

Trend, 2019–2024

Medicare prescriptions fell 32% from 2019 to 2024.

Medicare Part D prescriptions per year, all prescribers
  • 2019283,427
  • 2020268,406
  • 2021245,423
  • 2022224,762
  • 2023208,073
  • 2024193,873

Biggest change by state since 2019

  • Virginia −26%
  • Pennsylvania −27%
  • Oregon −29%
  • New Jersey −29%
  • Georgia −29%
  • North Carolina (smallest change) −36%
  • California (smallest change) −34%

From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.

What it looks like

Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.

American Health PAckaging

StrengthLooks likeImprint
4 mggray round tablet, 7 mm4941 V
8 mggray round tablet, 9 mm4942 V

Major Pharmaceuticals

StrengthLooks likeImprint
2 mggray round tablet, 7 mm4940 V
4 mggray round tablet, 7 mm4941 V
8 mggray round tablet, 9 mm4942 V

Par Health USA, LLC

StrengthLooks likeImprint
2 mggray round tablet, 7 mm4940 V
4 mggray round tablet, 7 mm4941 V
8 mggray round tablet, 9 mm4942 V
16 mggray round tablet, 9 mm4943 V

Remedyrepack Inc.

StrengthLooks likeImprint
16 mgwhite round tablet, 11 mmAC395

Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.

Industry payments about this drug

No industry payments to clinicians named this drug in 2025.

Recalls and shortages

Not on the FDA drug shortage list.

No FDA-reported recalls since 2020.

Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.